AU2002350751C1 - Compounds which can be used to diagnose and monitor diseases associated with the formation of amyloid protein fibrils - Google Patents

Compounds which can be used to diagnose and monitor diseases associated with the formation of amyloid protein fibrils Download PDF

Info

Publication number
AU2002350751C1
AU2002350751C1 AU2002350751A AU2002350751A AU2002350751C1 AU 2002350751 C1 AU2002350751 C1 AU 2002350751C1 AU 2002350751 A AU2002350751 A AU 2002350751A AU 2002350751 A AU2002350751 A AU 2002350751A AU 2002350751 C1 AU2002350751 C1 AU 2002350751C1
Authority
AU
Australia
Prior art keywords
chloro
hydroxyquinoline
iodo
complex
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002350751A
Other languages
English (en)
Other versions
AU2002350751B2 (en
AU2002350751A8 (en
AU2002350751A1 (en
Inventor
Carlos Piera Pena
Isabel Ramirez De Arellano Serna
Jorge Setoain Quinquer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CETIR CENTRE MEDIC SA
Catalana de Dispensacion SA
Barnatron SA
Original Assignee
Cetir Centre Medic S A
Catalana de Dispensacion SA
Barnatron SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cetir Centre Medic S A, Catalana de Dispensacion SA, Barnatron SA filed Critical Cetir Centre Medic S A
Publication of AU2002350751A8 publication Critical patent/AU2002350751A8/xx
Publication of AU2002350751A1 publication Critical patent/AU2002350751A1/en
Publication of AU2002350751B2 publication Critical patent/AU2002350751B2/en
Application granted granted Critical
Publication of AU2002350751C1 publication Critical patent/AU2002350751C1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C07D215/30—Metal salts; Chelates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C07D215/28—Alcohols; Ethers thereof with halogen atoms or nitro radicals in positions 5, 6 or 7

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Quinoline Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2002350751A 2002-11-18 2002-11-18 Compounds which can be used to diagnose and monitor diseases associated with the formation of amyloid protein fibrils Ceased AU2002350751C1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/ES2002/000537 WO2004045651A1 (es) 2002-11-18 2002-11-18 Compuestos utiles para el diagnostico y seguimiento de enfermedades relacionadas con la formación de fibrilas proteicas amiloides

Publications (4)

Publication Number Publication Date
AU2002350751A8 AU2002350751A8 (en) 2004-06-15
AU2002350751A1 AU2002350751A1 (en) 2004-06-15
AU2002350751B2 AU2002350751B2 (en) 2006-04-06
AU2002350751C1 true AU2002350751C1 (en) 2006-11-16

Family

ID=32319763

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002350751A Ceased AU2002350751C1 (en) 2002-11-18 2002-11-18 Compounds which can be used to diagnose and monitor diseases associated with the formation of amyloid protein fibrils

Country Status (8)

Country Link
US (1) US20080063599A1 (https=)
EP (1) EP1563852B1 (https=)
JP (1) JP2006514928A (https=)
AU (1) AU2002350751C1 (https=)
CA (1) CA2505506C (https=)
DE (1) DE60223729T2 (https=)
ES (1) ES2297024T3 (https=)
WO (1) WO2004045651A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005216949B2 (en) 2004-02-24 2011-09-22 The General Hospital Corporation Catalytic radiofluorination
US8257680B1 (en) 2004-02-24 2012-09-04 The General Hospital Corporation Catalytic radiofluorination
US9017724B2 (en) 2004-02-24 2015-04-28 The General Hospital Corporation Catalytic radiofluorination
JP5603074B2 (ja) 2006-09-08 2014-10-08 ピラマル イメージング ソシエテ アノニム １８ｆ標識物質のための化合物と方法
CA2978149C (en) 2008-03-21 2019-02-12 The General Hospital Corporation Inositol derivatives for the detection and treatment of alzheimer's disease and related disorders
US10781178B2 (en) 2015-08-12 2020-09-22 The General Hospital Corporation 8-hydroxyquinoline derivatives as diagnostic and therapeutic agents
CN110759952B (zh) * 2019-09-27 2021-04-20 广西师范大学 基于8-甲氧基喹啉构筑的钴配合物及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4279887A (en) * 1978-11-29 1981-07-21 Medi-Physics, Inc. Amides useful as brain imaging agents
US4360509A (en) * 1979-12-19 1982-11-23 Byk-Mallinckrodt Cil B.V. Vivo radioassay process
US5045303A (en) * 1985-05-17 1991-09-03 Neorx Corporation Radiohalogenated small molecules for protein labeling
AU720643B2 (en) * 1996-08-13 2000-06-08 P.N. Gerolymatos S.A. Use of the chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of Alzheimer's disease
JP3772506B2 (ja) * 1998-01-19 2006-05-10 三菱化学株式会社 キノリノール誘導体、その金属錯体およびそれを用いた有機電界発光素子
US20020025944A1 (en) * 2000-04-28 2002-02-28 Bush Ashley I. Use of clioquinol for the therapy of Alzheimer's disease
US6589504B1 (en) * 2000-09-22 2003-07-08 Pharmacia & Upjohn Company Compounds and methods for diagnosing and treating amyloid-related conditions

Also Published As

Publication number Publication date
DE60223729T2 (de) 2008-10-30
ES2297024T3 (es) 2008-05-01
AU2002350751B2 (en) 2006-04-06
AU2002350751A8 (en) 2004-06-15
CA2505506C (en) 2008-07-08
EP1563852A1 (en) 2005-08-17
AU2002350751A1 (en) 2004-06-15
DE60223729D1 (de) 2008-01-03
WO2004045651A1 (es) 2004-06-03
CA2505506A1 (en) 2004-06-03
US20080063599A1 (en) 2008-03-13
EP1563852B1 (en) 2007-11-21
JP2006514928A (ja) 2006-05-18

Similar Documents

Publication Publication Date Title
JP4317955B2 (ja) アミロイド斑凝集阻害剤および診断用造影剤
JP7500551B2 (ja) 前立腺特異的膜抗原（ｐｓｍａ）の標識化阻害剤、画像化剤としてのそれらの使用、及びｐｓｍａ発現がんの処置のための医薬剤
Zhuang et al. IBOX (2-(4′-dimethylaminophenyl)-6-iodobenzoxazole): a ligand for imaging amyloid plaques in the brain
EP2170075B1 (en) Labeled inhibitors of prostate specific membrane antigen (psma), biological evaluation, and use as imaging agents
JP4436928B2 (ja) スチルベン誘導体、およびアミロイド斑の結合および画像化のためのその使用
AU2002258915A1 (en) Amyloid plaque aggregation inhibitors and diagnostic imaging agents
CN101355940B (zh) 用于检测具有至少一种促淀粉样变蛋白的淀粉样沉积物的体内或体外方法
JP2010524965A (ja) ジフェニル−ヘテロアリール誘導体並びにアミロイド斑への結合及び画像化のためのその使用
AU2002350751C1 (en) Compounds which can be used to diagnose and monitor diseases associated with the formation of amyloid protein fibrils
AU2024343597A1 (en) Dansylamide-modified compounds targeting psma, preparation method therefor, and use thereof
EP1175388B1 (en) Spect imaging agents for serotonin transporters
Neumaier et al. Synthesis and evaluation of 18F-fluoroethylated benzothiazole derivatives for in vivo imaging of amyloid plaques in Alzheimer's disease
WO2008128129A1 (en) Halo-stilbene derivatives and their use for binding and imaging of amyloid plaques
DE102023133281B4 (de) Radiotracer und Präkursoren für diese Radiotracer sowie Verwendung dieser Radiotracer als Diagnostika und Therapeutika
WO2026037958A1 (en) Fapi theranostic compounds assembled with tetrazine ligation
TW202606691A (zh) 糖尿病腎病診斷藥物及應用
HK1215249B (en) Labeled inhibitors of prostate-specific membrane antigen (psma), biological evaluation, and use as imaging agents

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 18, NO 27, PAGE(S) 7372 UNDER THE HEADING APPLICATIONS OPI - NAME INDEX UNDER THE NAME CETIRCENTRE MEDIC, S.A., APPLICATION NO. 2002350751, UNDER INID (71) CORRECT THE NAME TO READ BARNATRON, S.A., CATALANA DE DISPENSACION, S.A. AND CETIR CENTRE MEDIC, S.A.

Free format text: IN VOL 17, NO 12, PAGE(S) 3425 UNDER THE HEADING COMPLETE APPLICATIONS FILED - NAME INDEX UNDER THENAME CETIR CENTRE MEDIC, S.A., APPLICATION NO. 2002350751, UNDER INID (71) CORRECT THE NAME TO READ BARNATRON, S.A., CATALANA DE DISPENSACION, S.A. AND CETIR CENTRE MEDIC, S.A.

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 14 JUN 2006.

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 14 JUN 2006

MK14 Patent ceased section 143(a) (annual fees not paid) or expired